Stocks and Investing
Stocks and Investing
Tue, February 27, 2024
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
[ Tue, Feb 27th 2024
] - WOPRAI
Kevin Steinke Maintained (CCRN) at Buy with Decreased Target to $24 on, Feb 27th, 2024
Kevin Steinke of Barrington Research, Maintained "Cross Country Healthcare, Inc." (CCRN) at Buy with Decreased Target from $26 to $24 on, Feb 27th, 2024.
Kevin has made no other calls on CCRN in the last 4 months.
There are 5 other peers that have a rating on CCRN. Out of the 5 peers that are also analyzing CCRN, 4 agree with Kevin's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tobey Sommer of "Truist Securities" Maintained at Hold with Decreased Target to $16 on, Thursday, February 22nd, 2024
- Constantine Davides of "JMP Securities" Initiated at Hold on, Wednesday, December 6th, 2023
- A.J. Rice of "UBS" Initiated at Hold and Held Target at $22 on, Thursday, November 30th, 2023
- Brian Tanquilut of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $21 on, Friday, November 3rd, 2023
This is the rating of the analyst that currently disagrees with Kevin
- Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $21 on, Thursday, February 22nd, 2024
Contributing Sources